LAP3 promotes glioma progression by regulating proliferation, migration and invasion of glioma cells

He, Xiaojuan; Huang, Qiyu; Qiu, Xiaojun; Liu, Xianchen; Sun, Guan; Guo, Jun; Ding, Zongmei; Yang, Lixiang; Ban, Na; Tao, Tao; Wang, Dongling

doi:10.1016/j.ijbiomac.2014.10.021

Cited by 27 publications

(24 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This recycling process occurs constantly in healthy and transformed cells and is orchestrated by proteasomes and aminopeptidases (Saric et al 2004). Aminopetidases such as serine aminopeptidase dipeptidyl peptidase (Busek et al 2012), leucine aminopeptidase 3 (He et al 2015) and methionine aminopeptidase 2 (Dasgupta et al 2005) play a role in glioma. However, no treatment that involves aminopeptidases has been proven to be effective in glioma.…”

Section: Metabolic Compensations To Anti-tumor Therapymentioning

confidence: 99%

Glutamate and α-ketoglutarate: key players in glioma metabolism

2016

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM), or grade IV astrocytoma, is the most common type of primary brain tumor. It has a devastating prognosis with a 2-year-overall survival rate of only 26 % after standard treatment, which includes surgery, radiation, and adjuvant chemotherapy with temozolomide. Also lower grade gliomas are difficult to treat, because they diffusely spread into the brain, where extensive removal of tissue is critical. Better understanding of the cancer’s biology is a key for the development of more effective therapy approaches. The discovery of isocitrate dehydrogenase (IDH) mutations in leukemia and glioma drew attention to specific metabolic aberrations in IDH-mutant gliomas. In the center of the metabolic alterations is α-ketoglutarate (αKG), an intermediate metabolite in the tricarboxylic acid (TCA) cycle, and the associated amino acid glutamate (Glu). This article highlights the role of these metabolites in glioma energy and lipid production and indicates possible weak spots of IDH-mutant and IDH-wt gliomas.

show abstract

Section: Metabolic Compensations To Anti-tumor Therapymentioning

confidence: 99%

Glutamate and α-ketoglutarate: key players in glioma metabolism

2016

View full text Add to dashboard Cite

show abstract

“…As a cell surface aminopeptidase, leucine aminopeptidase 3 (LAP3) is responsible for catalyzing the hydrolysis of leucine residues. Accumulating evidence has revealed that overexpression of LAP3 correlated with prognosis of several cancers, such as esophageal squamous cell carcinoma (ESCC), glioma, and HCC (He et al, 2015). Meanwhile, a recent study on ovarian cancer cells has indicated that suppression of LAP3 inhibited cell migration and invasion through its target genes fascin and MMP-2/9 (Wang et al, 2015b), underlying its important roles in regulating cancer cell metastasis.…”

Section: Resultsmentioning

confidence: 99%

The Identification and Analysis of mRNA–lncRNA–miRNA Cliques From the Integrative Network of Ovarian Cancer

Zhou

Zheng

et al. 2019

Front. Genet.

View full text Add to dashboard Cite

Ovarian cancer is one of the leading causes of cancer mortality in women. Since little clinical symptoms were shown in the early period of ovarian cancer, most patients were found in phases III–IV or with abdominal metastasis when diagnosed. The lack of effective early diagnosis biomarkers makes ovarian cancer difficult to screen. However, in essence, the fundamental problem is we know very little about the regulatory mechanisms during tumorigenesis of ovarian cancer. There are emerging regulatory factors, such as long noncoding RNAs (lncRNAs) and microRNAs (miRNAs), which have played important roles in cancers. Therefore, we analyzed the RNA-seq profiles of 407 ovarian cancer patients. An integrative network of 20,424 coding RNAs (mRNAs), 10,412 lncRNAs, and 742 miRNAs were construed with variance inflation factor (VIF) regression method. The mRNA–lncRNA–miRNA cliques were identified from the network and analyzed. Such promising cliques showed significant correlations with survival and stage of ovarian cancer and characterized the complex sponge regulatory mechanism, suggesting their contributions to tumorigenicity. Our results provided novel insights of the regulatory mechanisms among mRNAs, lncRNAs, and miRNAs and highlighted several promising regulators for ovarian cancer detection and treatment.

show abstract

“…Dysregulation of LAP3 expression could alter peptide activation, thus leading to changes of cell proliferation, invasion, and angiogenesis [ 20 , 21 ]. Studies have shown that LAP3 is overexpressed in several malignant tumors, including ovarian epithelial malignancy, gliomas, esophageal squamous cell carcinoma, and hepatocellular carcinoma [ 21 – 24 ].…”

Section: Discussionmentioning

confidence: 99%

Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers

2017

View full text Add to dashboard Cite

We hypothesized that cancer tissue immunogens – antigens capable of inducing specific antibody production in patients – are promising targets for development of precision diagnostics and humoral immunotherapies. We developed an innovative immuno-proteomic strategy and identified new immunogenic markers of colon cancer. Proteins from cancers and matched normal tissues were separated by 2D gel electrophoresis and blotted with serum antibodies from the same patients. Antibody-reactive proteins were sequenced by mass spectrometry and validated by Western blotting and immunohistochemistry. 170 serum antibody-reactive proteins were identified only in cancerous but not matched normal. Among these, proteasome subunit alpha type 1 (PSA1), leucine aminopeptidase 3 (LAP3), annexin A3 (ANXA3), and maspin (serpin B5) were reproducibly found in tissues from three patients. Differential expression patterns were confirmed in samples from eight patients with various stages of colon adenocarcinoma and liver metastases. These tumor-resident proteins and/or their associated serum antibodies may be promising markers for colon cancer screening and early diagnosis. Furthermore, tumor tissue-specific antibodies could potentially be exploited as immunotherapeutic targets against cancer. More generally, proteomic profiling of antibody-inducing cancer-associated immunogens represents a powerful generic method for uncovering the tumor antigen-ome, i.e., the totality of immunogenic tumor-associated proteins.

show abstract

LAP3 promotes glioma progression by regulating proliferation, migration and invasion of glioma cells

Cited by 27 publications

References 31 publications

Glutamate and α-ketoglutarate: key players in glioma metabolism

Glutamate and α-ketoglutarate: key players in glioma metabolism

The Identification and Analysis of mRNA–lncRNA–miRNA Cliques From the Integrative Network of Ovarian Cancer

Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers

Contact Info

Product

Resources

About